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Immunity
Previewsof IL-1R1-mediated proinflammatory
responses. The relevance of these find-
ings to explain the mechanistic underpin-
ning for various pathological conditions
associated with sustained inflamma-
tion in humans now appears as amanage-
able challenge. Thus, what can make
necrosis ‘‘silent’’ by keeping a lid on
IL-1a? Now, the answer is clear—it is
IL-1R2.
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In this issue of Immunity, Cortez-Retamozo et al. (2013) demonstrate that the increased production of
angiotensin II in tumor-bearing mice induces the expansion of macrophage progenitors and the supply of
macrophages.Macrophages contribute to all facets of
tumor progression and thus are an impor-
tant component of the tumor microenvi-
ronment. Their role in tumor development,
angiogenesis, tumor cell invasion, and
metastases is well established (Qian and
Pollard, 2010) (Qian et al., 2011). For a
number of years, these cells have been
considered to be important negative
regulators of immune responses in cancer
(Mantovani and Sica, 2010) (Gabrilovich
et al., 2012). In a preclinical model, the
blockade of macrophage recruitment
improved the survival of mammary
tumor-bearing mice by slowing primary
tumor development and reducing pulmo-
nary metastasis (DeNardo et al., 2011).
There is now ample evidence demon-
strating that tumor-derived factors drive
an increased production of macrophages
in cancer. It is believed that different
growth factors, such as M-CSF (CSF-1),
play major roles in this process. In this
issue of Immunity, Cortez-Retamozo
et al. (2013) demonstrate that peptide
hormone angiotensine II (AngII) mightcontribute to the increased production of
macrophages in cancer by amplifying
self-renewing hematopoietic stem cells
and macrophage progenitors.
AngII is an oligopeptide that belongs to
the renin-angiotensin system, which regu-
lates blood pressure. Its precursor, angio-
tensin I (Ang I,) is derived from a2-globulin
angiotensinogen produced by the liver
after cleavage of a 10 amino acid peptide
by renin. Ang I is converted to AngII by the
angiotensin-converting enzyme (ACE).
Ang II acts as a hormone to affect blood
pressure via manymechanisms, including
cardiovascular, renal, adrenal, and other
systems. ACE inhibitors are major drugs
used in the treatment of high blood
pressure. Previous studies have demon-
strated that AngII might promote inflam-
mation and that it interacts with mono-
cytes and mobilizes these cells from the
splenic reservoir. In the current study,
Cortez-Retamozo et al. used a mouse
model of lung adenocarcinoma caused
by the activation of oncogene Kras and
inactivation of the tumor suppressorgene p53. These mice developed lung
cancer after an intranasal infection with
Cre-recombinase-containing adenovirus.
The authors found that tumor-bearing
mice had a significantly higher concentra-
tion of AngII in plasma than did control
mice. Treatment of naive mice with AngII
resulted in increased colony-forming
activity of splenocytes, suggesting that
AngII might have an effect on myelopoie-
sis. This conclusion was further sup-
ported by the fact that AngII-treated
mice had a higher proportion of myeloid
progenitors. The expansion of progenitor
cell numbers occurred in the spleen but
not in bone marrow. AngII is a potent
regulator of hemodynamics. Thus, it might
have an effect on cell mobilization and the
expansion of myeloid cell numbers. To
address this concern, Cortez-Retamozo
et al. used vasodilator hydralazine and
demonstrated that this did not affect the
AngII-inducible expansion of myeloid
progenitor cell numbers. Furthermore,
the effect of AngII on myeloid cells was
found to be mediated by its interactionFebruary 21, 2013 ª2013 Elsevier Inc. 205
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Figure 1. AngII-AGTR1A Signaling
Promotes Tumor-Associated Macrophages
Bone marrow myeloid progenitors interact with
tumor-produced AngII, which downregulates
S1P1 and causes its entrapment in spleens, where
it proliferates and differentiates to monocytes.
After migration to the tumor site, monocytes
become tumor-associated macrophages.
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Previewswith a specific receptor, AGTR1A, on
hematopoietic cells but not on nonhema-
topoietic cells. Using an elegant parabiont
experimental system, the authors demon-
strated that AngII causes retention of
myeloid progenitors in the spleen. This
effect was mediated by downregulation
of the sphingosine-1-phosphate receptor
1 (S1P1), which was down-stream of
AGTR1A signaling. S1P1 plays a major
role in regulating leukocyte egress from
peripheral lymphoid organs. Thus, the
inhibition of S1P1 by AngII can explain
the sequestration of myeloid cells in the
spleen. To block AngII production, the
authors used the ACE inhibitor enalapril,
a drug that is commonly used in the treat-
ment of high blood pressure. A 5 day
treatment of tumor-bearing mice with
enalapril did not affect tumor burden,
but it did decrease the expansion of
myeloid progenitor numbers. An ex-
tended 3 week treatment decreased the206 Immunity 38, February 21, 2013 ª2013 Eexpansion of myeloid progenitor numbers
in the spleen but not in bone marrow, and
it reduced both the amplification of mono-
cytes in the spleen and macrophage
accumulation in the lungs. The number
of tumor lesions in the lungs decreased
significantly, and animal survival thus
increased, in mice treated with enalapril
but not in mice treated with hydralazine.
The authors also observed the increased
production of angiotensinogen in 16
out of 44 samples of non-small-cell lung
cancers (NSCLCs) and found the in-
creased expression of angiotensinogen
mRNA in the publicly available data set
of NSCLC tumor tissues.
This study suggests a mechanism by
which tumors might control the expansion
of macrophage numbers. This mecha-
nism involves AngII mediation of the
redistribution of myeloid progenitors and
their increased expansion in the spleen
(Figure 1). Because of the role of AngII,
the study also suggests that ACE inhibi-
tors might have a role in cancer treatment.
However, as with any good research,
many questions remain unanswered.
The significance of these findings for
cancer patients needs to be demon-
strated. If a substantial proportion of
cancer patients have an increased level
of AngII, this should result in increased
blood pressure in those patients. This
would be especially evident in patients
with a substantial tumor burden. How-
ever, at this moment, there is no evidence
that even advanced stages of cancers are
associated with high blood pressure.
Moreover, large cohort studies that have
involved treatment of cancer patients
with ACE inhibitors have not provided
clear evidence supporting the antitumor
effect of these drugs (Wilop et al., 2009).
It is important to point out that macro-
phage number expansion was not studied
in those trials. In addition, the described
mechanism of redistribution of myeloid
progenitors to the spleen might not be
directly applicable to humans because
there is little evidence that the spleen in
cancer patients plays as important a role
as a site of extramedullary hematopoiesis
does in tumor-bearing mice. The issue of
the association between blood pressure
and macrophage expansion also needslsevier Inc.clarification. The authors showed that
the effect of AngII was not associated
with blood pressure. However, in a recent
study, Jun et al. came to the opposite
conclusion (Jun et al., 2012). In that study,
Jun et al. showed that chronic AngII infu-
sion resulted in a 250% increase in bone
marrow inflammatory cells. This effect
was substantially reduced by the attenua-
tion of AngII-induced hypertension. Inter-
estingly, targeted expression of ACE in
monocytes and macrophages increased
resistance to the growth of melanoma
via enhanced immune responses (Shen
et al., 2008). This suggests that accumu-
lation of AngII inmonocytesmight actually
promote antitumor immunity as opposed
to their being an effect of AngII onmyeloid
progenitors. Future studies will clarify
what role AngII might play in the regulation
of macrophage accumulation in cancer.
This report provides evidence supporting
the interplay between renin-angiotensin
and the immune system and provides
a unique mechanism by which a tumor
might control the expansion of myeloid
cell numbers.
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